Related Experiment Video
Updated: Mar 21, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
18.3K
Comparative assessment of bioanalytical method validation guidelines for pharmaceutical industry
Naveen Kadian1, Kanumuri Siva Rama Raju2, Mamunur Rashid1
1Department of Pharmacokinetics and Metabolism, CSIR-Central Drug Research Institute, Lucknow, India.
Journal of Pharmaceutical and Biomedical Analysis
|May 15, 2016
Summary
Bioanalytical method validation is crucial for routine use. This review compares global regulatory guidelines, highlighting variations and similarities to aid method design and validation.
Area of Science:
- Analytical Chemistry
- Pharmaceutical Sciences
Background:
- Bioanalytical method validation is essential for drug development and regulatory submission.
- The United States Food and Drug Administration (USFDA) guidelines have historically set the standard for bioanalytical method validation.
- Harmonization efforts aim to standardize validation across global regulatory agencies.
Purpose of the Study:
- To compare and contrast bioanalytical method validation guidelines from major global regulatory authorities.
- To identify variations and similarities in acceptance criteria and methodologies.
- To discuss key evaluation parameters like matrix effect and stability for comprehensive method design.
Main Methods:
- Review of bioanalytical method validation guidelines from key regulatory bodies (USFDA, EMA, ANVISA, MHLW).
- Comparative analysis of guideline content, focusing on acceptance criteria and validation parameters.
- Inclusion of discussions on matrix effect, incurred sample reanalysis, and stability studies.
Main Results:
- While general agreement exists, significant differences in acceptance criteria and methodology persist among regulatory agencies.
- The 2013 USFDA draft guideline represents an effort towards global harmonization.
- Key parameters like matrix effect and stability are critical for robust bioanalytical methods.
Conclusions:
- Understanding guideline variations is vital for successful bioanalytical method validation.
- This review provides a consolidated resource to facilitate the design of methods compliant with multiple regulatory requirements.
- Adherence to harmonized validation practices ensures data integrity and regulatory acceptance worldwide.
More Related Videos
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
5.6K
08:59An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
Published on: December 3, 2020
8.9K
Related Concept Videos
01:15Data Validation
3.5K
Method validation is a crucial process in analytical chemistry designed to confirm that a given method consistently produces reliable and high-quality results. This process is essential when a method is applied to different sample matrices or when procedural modifications are made, ensuring that the results meet acceptable standards across various applications.
Key parameters for method validation include:
Key parameters for method validation include:
3.5K
01:16Bioequivalence Data: Statistical Interpretation
312
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
312
01:13Bioequivalence studies: Biowaivers
377
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
377
01:14Drug Dissolution: Requirements and Profile Comparison
390
The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
390
01:16Bioequivalence: Overview
2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
01:26Pharmaceutical Equivalents
254
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
254